Position in NVS
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$203,736
New position
Shares Held
1,300
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#1,313
of 1,603 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Westover Capital Advisors, LLC holds $13,813,106 across 9 Drug Manufacturers - General names. NVS ranks #9 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
3,728 | $4,471,475 | |
| 2 | ABBV |
AbbVie Inc.
|
8,549 | $2,151,270 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
15,885 | $2,006,910 | |
| 4 | JNJ |
Johnson & Johnson
|
6,016 | $1,527,883 | |
| 5 | MRK |
Merck & Co., Inc.
|
11,716 | $1,505,506 | |
| 6 | AMGN |
Amgen Inc
|
2,375 | $860,035 | |
| 7 | AZN |
Astrazeneca PLC
|
4,458 | $845,325 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
4,182 | $240,966 |
All Filings in NVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $203,736 | 1,300 | Shares | Sole | 2026-08-04 | |
| No filing history on record for this holder in this stock. | ||||||